

Cumulative Index 1988

Volume 15

<i>March</i>	TWIN PREGNANCY, pp 1-162
<i>June</i>	INFECTIOUS COMPLICATIONS OF PREGNANCY, pp 163-419
<i>September</i>	CARDIOVASCULAR DISEASE IN THE NEONATE, pp 421-726
<i>December</i>	CURRENT CONTROVERSIES IN PERINATAL CARE, pp 727-1006

Note: Pages numbers of article titles are in **boldface** type.

- Abortion, spontaneous, and enterovirus infections, 236
- Acardia, and placental changes, 32
- Actin, in heart maturation, 436-438
 - gene regulation, 438
 - and hormonal effects on cardiac growth, 437-438
 - isoform shifts, 436-437
 - during pressure overload, 437
- Acyanosis, congenital heart disease with increased pulmonary blood flow, 524-532
- Afterload-reducing agents. *See Inotropic and afterload-reducing agents.*
- Aldosterone, and body fluid homeostasis, 450, 452
- Algorithm, anesthesia for twin births, 120
- Alimentary system, maternal, in twin pregnancy, 44
- Amiloride, 460-461
- Amniocentesis, 62-63
 - Doppler ultrasound, 63
 - for fetal lung maturation, 63
 - genetic, 62-63
- Amniotic fluid, human surfactant from, 892-893
- Amrinone, 483
- Analgesia, labor, 111-113
- Anemia, antenatum complication, 83
- Anesthesia, for open heart surgery, 663-665
 - for twin delivery, **107-122**
 - algorithm, 120
 - analgesia for labor, 111-113
 - cesarean section, 116-120
 - labor and delivery, 110-111
 - pathophysiology, 109-110
 - physiology, 107-108
 - vaginal delivery, 113-116
- Angiotensin converting enzyme inhibitors, 461
- Antibiotic therapy of newborns, **365-388**
 - administration route, 382
 - adverse effects, 386
 - bacterial infections, 367-368
 - blind therapy, 375-377
 - cephalosporins, third-generation, 380-381
 - diagnosis of infection, 368-372
 - dosage, 382
 - epidemiology, 366-367
 - evaluation, 380
 - incidence of infection, 365-366
 - monitoring of therapy, 384-385
 - new antibiotics, 381
 - pharmacology and pharmacokinetics, 372-375
 - policy, 375
 - problem areas, 377-380
 - toxicity, 385-386
 - treatment duration, 382-384
- Antibody fragments, digoxin-specific, 506-510
 - administration and dosage, 508-510
 - indications, 508
- Antigen detection systems, chlamydial infections, 341
- Antioxidants, and retinopathy of prematurity, 923-924

- Antiviral agents, and HIV infection in pregnancy, 195
- Aorta, closed heart surgery, 690-691
 coarctation of, 644-648
 native, 644-646
 recurrent and postoperative obstructions, 647-648
- Aortic arch, interrupted, 671-672
- Aortic valvular stenosis, 676, 692-696
- Aplastic crisis, 277-278
- Arrhythmias, cardiac, and sudden infant death syndrome, 699-712
 bradycardia, 706-708
 clinical presentation, 700-701
 congenital complete A-V block, diagnosis of, 708
 in utero therapy for, 708-711
 etiology, 708
 evaluation, 702
 followup of nonpaced infants, 711
 initial treatment, 703
 mechanisms, 701-702
 nonpharmacologic therapy, 706
 supraventricular tachycardia, 704-706
 tachycardias and cardiomyopathies, 702-703
 ventricular tachycardia, 703-704
 See also *Ventricular rhythm with intermediate rate (VRIR)*.
- Arthritis, and parvovirus B19, 278
- Asphyxia, birth, in twin pregnancy, 128
- ATPase, Ca, Mg-dependent, sarcoplasmic reticular, 440-442
- Atrial natriuretic factor, 451, 453
- Atrium, echocardiography of septal defect, 528-529
 right-to-left shunt, 545-546
 septectomy, 688-692
- Atrioventricular block, congenital complete, 708-711
 diagnosis, 708
 in utero therapy, 708-711
- Atrioventricular septal defects, echocardiography of, 532
- Autonomic nervous system, and digitalis glycosides, 496-497
- B19 virus. See *Parvovirus B19, human*.
- Baby Doe committees, 789-800
 assessment, 794-798
 ethical decisions, 794-795
 federal regulations and guidelines, 795-796
 legal problems, 796
 public image, 796-798
 assumptions and goals, 790-791
 ethical question types, 792-794
 origin, 789-790
- similarities and differences, 791-792
 suggestions, 798-799
 confidentiality, 799
 education, 798
 "grass roots" origins, 798
 hospital leadership, 798
 interdisciplinary composition, 798
 meetings and recommendations, 798
 membership terms, 799
 parent participation, 799
 public representation, 799
 record keeping, 799
- Bacterial infections, antibiotic therapy of
 newborn, 367-368
 after implantation, 173-174
 perinatal, 178-180
 Listeria monocytogenes, 180
 streptococci, group B, 178-180
- Bed rest, in antepartum management, 60-61
 and premature labor, 71-73
- Beta-sympathomimetic agents, 74
- Bilirubin-binding assays, 975-982
- "Biological clock," and premature rupture of membranes, 857-859
- Biopsy, endomyocardial, 651
- Birth weights, relation to gestational age and intrauterine growth failure, 777
 in teenage pregnancies, 933-935
 in twin pregnancy, 126-127, 142-144
- Blastomere separation, 16
- Blood flow, pulmonary, echocardiography in congenital heart disease, 524-532, 540-546
 renal, during transition to extrauterine life, 866
- Blood pressure measurement in neonates, 567-569
- Blood-brain barrier, physiology of, 966-968
- Body fluid homeostasis. See *Homeostasis of body fluids*.
- Bradycardia, 706-708
- Bronchopulmonary dysplasia, and fluid intake, 871-872
 vitamin E therapy, 959
- Bumetanide, 459
- Candidiasis, and HIV infection, 195
- Carbohydrate metabolism, maternal, in twin pregnancy, 44, 83-84
- Cardiomyopathies, dilated, digoxin effects, 503
 See also *Arrhythmias*.
- Cardiovascular disease in neonates, arrhythmias, cardiac, and sudden infant death syndrome, 699-712
 clinical presentation, 700-701
 evaluation, 702

- mechanisms, 701-702
- tachycardias and cardiomyopathies, 702-703
- body fluid homeostasis with congestive heart failure, 447-466
- closed heart surgery for congenital heart disease, 681-697
 - aortic valvular stenosis, 692-696
 - atrial septectomy, 688-692
 - coarctation of aorta, 690-691
 - palliative operations, 681-682
 - pulmonary artery banding, 684-688
 - systemic to pulmonary artery shunts, 682-684
- digitalis, 491-521
 - digoxin-like immunoreactive substances, 510-518
 - glycosides, 491-506
 - intoxication and Fab antibody fragments, 506-510
- echocardiography, two-dimensional and Doppler, 523-555
 - additional uses, 552-556
 - congenital heart disease, with acyanosis and increased pulmonary blood flow, 524-532
 - with cyanosis and decreased pulmonary vascularity, 540-546
 - with cyanosis and increased pulmonary vascularity, 546-552
 - with ventricular outflow obstruction, 532-539
 - limitations, 556-557
 - prenatal diagnosis, 557-562
- endocarditis, 587-608
 - complications, 602-603
 - diagnosis, 594-598
 - etiology, 592-594
 - incidence, 587-588
 - pathogenesis, 588-592
 - prognosis, 603
 - treatment, 598-601
- heart maturation, 421-446
- hypertensive neonates, 567-585
 - blood pressure measurement, 567-569
 - causes of, 570-573
 - clinical signs and symptoms, 573-575
 - epidemiology, 569-570
 - evaluation of, 575-577
 - management of, 577-579
 - prognosis, 579-580
- inotropic and afterload-reducing agents, 467-489
 - cardiac physiology, 467-471
 - developmental aspects, 471-472
 - inotropy, 473
 - vasoactive drug therapy, 473-479
 - vasodilators, 479-483
- interventional cardiac procedures, 633-658
 - balloon atrial septostomy, 634-645
 - blade atrial septostomy, 635-637
 - coarctation of aorta, 644-648
 - device occlusion, 648-650
 - dilation of pulmonary valve in cyanotic congenital heart disease, 652-653
 - endomyocardial biopsy, 651
 - foreign body retrieval, 651
 - percutaneous pericardial drainage, 651-652
 - stenosis of individual pulmonary veins, 652
 - valvular aortic stenosis, 641-644
 - valvular pulmonary stenosis, 637-641
- open repair of cardiac defects, 659-780
 - aortic valve stenosis/pulmonary valve stenosis, 676
 - monitoring and anesthesia, 662-665
 - myocardial preservation, 666-667
 - preoperative management, 661-662
 - pulmonary atresia with intact ventricular septum, 676-677
 - techniques of cardiopulmonary bypass and hypothermic arrest, 665-666
 - tetralogy of Fallot with or without pulmonary atresia, 675-676
 - total anomalous pulmonary venous connection, 668-675
 - transposition of great arteries, 667
- transesophageal pacing and electrocardiography, 619-631
 - diagnostic and therapeutic uses, 624-629
 - electrocardiography, 619-620
 - pacing, 620
 - techniques, 621-623
- ventricular rhythm with intermediate rate, 609-618
- Cardiovascular system, maternal, in twin pregnancy, 42-43
- Catheters, and echocardiography, 556
- Central nervous system, and digitalis glycosides, 497
- Cephalosporins, and chloramphenicol, for syphilis, 296
- third-generation, 380-381
- Cerclage, cervical, 61
- and premature labor, 73
- Cesarean section, twin pregnancy, 116-120
- Chlamydial infections, 321-350
 - diagnosis, 340-341
 - antigen detection, 341
 - cultures, 340
 - cytologic, 340
 - serologic, 340
 - microbiology, 322-325
 - neonatal infections, 335-340
 - conjunctivitis, 335-337
 - pneumonia of infancy, 337-340
 - and postpartum endometritis, 334-335

- Chlamydial infections (*Continued*)
 and pregnancy, 326-334
 adverse outcomes, 331-334
 epidemiology, 326-328
 immunologic factors, 328-331
 psitticosis during pregnancy, 325
 treatment, 341-344
 conjunctivitis, 343-344
 pneumonia, 344
 during pregnancy, 342-343
 Circulation, digitalis effects, 497-498
 Clots, echocardiography of, 553-555
 Coagulation, maternal, in twin pregnancy, 43
 Conception, infections before, 163-164
 Congenital anomalies in twins, antepartum complications, 80
 concordance, 150
 conjoined twins, 149-150
 morbidity, 132-133
 structural defects, 147-149
 Congenital heart disease, echocardiography of, 523-565
 acyanosis and increased pulmonary blood flow, 524-532
 with cyanosis and decreased pulmonary vascularity, 540-546
 with cyanosis and increased pulmonary vascularity, 546-552
 with ventricular outflow obstruction, 532-539
 See also *Surgery, closed heart*.
 Congenital infections, 163-188
 before conception, 163-164
 retroviruses, endogenous, 163-164
 before implantation, 164-166
 viral, 164-165
 after implantation, 166-175
 bacterial, 173-174
 nonspecific and indirect effects, 166
 protozoan, 174-175
 viral, 167-173
 perinatally acquired, 175-180
 bacterial, 178-180
 viral, 176-178
 tuberculosis, 315-316
 Congenital malformations, from influenza, 262-263
 mumps infection, 265
 parvovirus B19 infection, 279
 Congestive heart failure, angiotensin converting enzyme inhibitors, 461
 body fluid homeostasis, 451-453
 digoxin effects, 503-504
 diuretic effects, 455-461
 loop diuretics, 456-458
 potassium-sparing diuretics, 460-461
 thiazides, 460
 Conjunctivitis, chlamydial, 335-337, 343-344
 Contractility, myocardial, digoxin effects, 503-505
 Copper, maternal, in twin pregnancy, 45
 Cost-effectiveness, chemoprophylaxis for group B streptococci, 845-846
 Counseling and testing, HIV infection in pregnancy, 198-199
 Coxsackievirus infections. See *Echovirus and group B coxsackievirus infections*.
 Cyanosis in congenital heart disease, with decreased pulmonary vascularity, 540-546
 with increased pulmonary vascularity, 546-552
 Cytomegalovirus, congenital infections, 168-170
 fetal infection, 205-208
 maternal infection, 203-205
 maternofetal transmission, 205
 prevention, 208
 in TORCH complex, 730
 Death of one fetus, 65, 81-82
 Delivery, of tiny infant, effects on outcome, 778-780
 Delivery of twins, anesthesia, 107-122
 algorithm, 120
 analgesia, 111-113
 cesarean section, 116-120
 labor and delivery, 110-111
 pathophysiology, 109-110
 physiology, 107-108
 vaginal delivery, 113-116
 management, 93-106
 general preparations, 94-96
 postpartum care, 104
 schemes for, 96-101
 technique of, 101-103
 unsuspected twins, 103-104
 trauma of twin pregnancy, 5-6
 Device occlusion, 648-650
 Diabetes, infant cardiomyopathy, 552-553
 maternal, 83-84
 Diagnosis, in antepartum management, 55-57
 of placental zygosity, 20-25
 of twin pregnancy, 8-10
 ultrasonography role, 57
 Diaphragmatic hernia, congenital, 950-951
 Diet, in antepartum management, 60
 Digitalis, 491-521
 digoxin-like immunoreactive substances, 510-518
 pregnancy, preeclampsia, and hereditary hypertension, 517-518
 sodium homeostasis and third factor, 511-516
 glycosides, 491-506

- administration and dosage, 506
- in cardiac failure, 497-498
- cellular effects, 493
- digoxin pharmacokinetics, 498-503
- indications for, 503-506
 - myocardial contractility, 503-505
 - for supraventricular tachycardias, 505-506
- pharmacologic actions of, 493-497
 - autonomic nervous system, 496-497
 - cardiac, 494
 - central nervous system, 497
 - vascular, 494
- receptors, 492-493
- intoxication and digoxin-specific Fab antibody fragments, 506-510
- Digoxin-like immunoreactive substances, 510-518
 - in neonates, 510-511
 - in pregnancy, 511
 - and renal failure, 511
 - sodium homeostasis and third factor, 511-516
 - in newborn, 516-517
 - pregnancy, preelampsia, and hereditary hypertension, 517-518
- Diuresis, and respiratory distress syndrome, 870-871
- Diuretics, in congestive heart failure, 455-461
 - loop, 456-458
 - potassium-sparing, 460-461
 - thiazides, 460
- DNA viruses, congenital infections, 171
- Dobutamine, 475-477
- Dopamine, 474-475
- Drug monitoring, antibiotic therapy of newborn, 384-385
- Echocardiography
 - in neonatal endocarditis, 596-597
- Echocardiography, two-dimensional and Doppler, 523-565
 - catheters, 556
 - clots and vegetations, 553-555
 - congenital heart disease, with acyanosis and increased pulmonary blood flow, 524-532
 - atrial septal defect, 528-529
 - atrioventricular septal defects, 532
 - patent ductus arteriosus, 524-528
 - ventricular septal defects, 529-532
 - with cyanosis and decreased pulmonary vascularity, 540-546
 - atrial right-to-left shunt, 545-546
 - ventricular right-to-left shunt, 540-545
 - with cyanosis and increased pulmonary vascularity, 546-552
 - arterial markings, 546-549
 - venous markings, 549-552
 - with ventricular outflow obstruction, 532-539
 - left ventricular outflow obstruction, 533-538
 - right ventricular outflow obstruction, 538-539
- infant of diabetic mother cardiomyopathy, 552-553
- limitations, 556-557
- prenatal diagnosis of congenital heart disease, 557-562
 - examination techniques, 558-559
 - indications, 558
 - rhythm abnormalities *in utero*, 559-561
 - structural and functional abnormalities *in utero*, 559
 - ultrasound effects on fetus, 561-562
- tumors, 555-556
- Echovirus and group B coxsackievirus infections, 233-246
 - animal studies, 234-235
 - enterovirus, neonatal infections, 236-240
 - clinical manifestations, 238-239
 - incidence, 236-237
 - mechanisms of transmission, 237-238
 - severity and outcome, 239-240
 - nomenclature, 233
 - nonpolio infections in pregnancy, 235-236
 - epidemiology and clinical disease, 234
 - history, 233
 - in newborn nurseries, 240-241
- Electrocardiography. *See Transesophageal pacing and electrocardiography.*
- Electrolytes, maternal, in twin pregnancy, 45-47
 - See also Fluid and electrolyte therapy, premature infant.*
- Electrophysiology, and digitalis glycosides, 494
- Embryology of twinning, 15-19
 - dizygous, 19
 - monozygous, blastomere separation, 16
 - inner-cell mass duplication, 16-19
 - and neonatal problems, 141-142
- Encephalitis, and herpes simplex virus infections, 907-908
- Endocarditis, neonatal, 587-608
 - complications, 602-603
 - diagnosis of, 594-598
 - blood culture, 595-596
 - clinical findings, 594-595
 - echocardiography, 596-597
 - laboratory findings, 595, 597-598
 - etiology of, 592-594
 - incidence, 587-588
 - pathogenesis of, 588-592

- Endocarditis (*Continued*)
 pathogenesis of, infective, 590-591
 nonbacterial thrombotic, 588-590
 prognosis, 603
 treatment, 598-602
- Endometritis, postpartum, and chlamydia, 334-335
- Enterocolitis, necrotizing, 151
- Enterovirus infections. *See Echovirus and group B coxsackievirus infections.*
- Environment, during transition to extrauterine life, 867-869
- Epidemiology, and antibiotic therapy of newborn, 366-367
 chlamydial infections, 326-328
 enterovirus infections, 234
 human immunodeficiency virus (HIV), 189-190
 hypertension in neonates, 569-570
 measles, 267-268
 parvovirus B19, 276-277
 syphilis, gestational and congenital, 287-289
 of twin pregnancy, 123-140
- Epinephrine, 478-479
- Epstein-Barr virus, 221-224
 fetal infection, 223-224
 maternal infection, 221-222
 maternofetal transmission, 222-223
 prevention, 224
 in TORCH complex, 736-740
 background, 736
 laboratory diagnosis, 736-737
 and pregnancy, 737-740
- Erythema infectiosum (fifth disease), 277
- Erythromycin, for syphilis, 294-295
- Ethacrynic acid, 459
- Ethics committees. *See Baby Doe committees.*
- Extracellular fluid volume, 449-451
- Extracorporeal membrane oxygenation. *See Oxygenation, extracorporeal membrane.*
- Eye, herpes infections, 908
- Fetus, antenatal management, 61-62
 death of one, 65, 81-82
 echocardiography, two-dimensional and Doppler, 557-562
 examination techniques, 558-559
 indications for, 558
 rhythm abnormalities in utero, 559-561
 structural and functional abnormalities in utero, 559
 ultrasound effects, 561-562
 infections, cytomegalovirus, 205-208
 Epstein-Barr virus, 223-224
 herpes simplex, 210-213
 influenza, 261-262
 measles, 269-270
 parvovirus B19, 278-280
 rubella, 250-253
 syphilis, 290-291
 tuberculosis, 306-308
 varicella-zoster, 217-219
 monstrosities, and placental changes, 32
 in twin pregnancy, growth, 47-48
 lung maturity, 48, 74-75
 ultrasonography, 58-59
 umbilical cord measurement, 48-49
- Fetus compressus, 32
- Fetus papyraceous, 32
- Fibroelastosis, endocardial, 265-266
- Fibronectin, for neonatal sepsis, 767
- Fluid and electrolyte therapy, premature infant, 863-878
 homeostasis during transition to extrauterine life, 864-869
 body water composition, 864-866
 environment impact, 867-869
 renal function, 866-867
 metabolic basis for maintenance, 864
 pathophysiology of disease of prematurity, 869-874
 bronchopulmonary dysplasia, 871-872
 diuresis and respiratory distress syndrome, 870-871
 very low birth weight infant, 873-874
- Foreign body retrieval, 651
- Furosemide, 458-459
- Gap-junction formation, and retinopathy, 921-922
- Gene regulation of cardiac actin, 438
- Gestational age, antenatal and postnatal assessment of, 776-777
 relation to birth weight and intrauterine growth failure, 777
- Glomerulus, during transition to extrauterine life, 866
- Granulocyte transfusions, 758-761
- Growth, cardiac, in hemodynamic overload, 434
 hormonal effects, 434-436
 and development of twins, 47-48, 151-153
 abnormalities, 4
 intrauterine retardation, 126-127, 142-144
 twin discordance, 80-81, 150
 ultrasonography, 58-59
 relation to birth weight and gestational age, 777
- Guidelines, AAP, Baby Doe committees, 795-796

- Heart, congenital disease, with acyanosis and increased pulmonary blood flow, 524-532
 patent ductus arteriosus, 524-528
 maturation of, 421-446
 biochemical basis, 421-427
 myofibrils, 427
 sarcolemma, 426-427
 sarcoplasmic reticulum, 423-425
 molecular basis, 427-440
 actin, gene regulation, 438
 developmental regulation, 433-434
 during pressure overload, 437
 growth, hemodynamic overload, 434
 heavy-chain distribution, 430-431
 hormonal effects, 434-436
 myosin, 428-430
 hormonal effects on growth, 437-438
 interrupted aortic arch, 671-672
 isoform shifts, 436-437
 light-chain distribution, 431-433
 tropomyosin, 438-439
 troponin, 440
 open repair of defects, 659-680
 aortic valve stenosis/pulmonary valve stenosis, 676
 monitoring and anesthesia, 662-665
 myocardial preservation, 666-667
 preoperative management, 661-662
 prostaglandin E₁, 661-662
 pulmonary atresia with intact ventricular septum, 676-677
 specific lesions, 667-670
 total anomalous pulmonary venous connection, 668-670
 truncus arteriosus, 672-675
 transposition of great arteries, 667
 techniques of cardiopulmonary bypass and hyperthermic arrest, 665-666
 tetralogy of Fallot with or without pulmonary atresia, 675-676
 physiology in neonates, 467-471
 protein regulation of cytosolic calcium, 440-442
 phospholamban, 442
 sarcolemmal, 442
 sarcoplasmic reticular Ca, Mg-dependent ATPase, 440-442
 Hemodynamics, and cardiac growth, 434
 Hemorrhage, periventricular/intraventricular, vitamin E therapy, 560
 Hepatitis B virus, congenital infections, 177-178
 Herpes simplex virus infections, 903-916
 congenital infections, 170-171, 176-177
 diagnosis, 908-910
 clinical evaluation, 908-909
 laboratory assessment, 909-910
 epidemiology of genital HSV-2 infections, 903-905
 fetal and neonatal infections, 210-213
 and HIV infection, 193-194
 maternal infection, 208-210
 maternofetal transmission, 210
 neonatal, 905-908
 acquisition of infection, 905
 clinical presentation, 906
 intrapartum and postpartum infection, 906-908
 intrauterine infection, 906
 pathogenesis, 905-906
 in pregnancy, 203-231
 cytomegalovirus, 203-208
 fetal infection, 205-208
 maternal infection, 203-205
 maternofetal transmission, 205
 prevention, 208
 Epstein-Barr virus, 221-224
 fetal infection, 223-224
 maternal infection, 221-222
 prevention, 224
 herpes simplex, 208-215
 fetal and neonatal infections, 210-213
 maternal infection, 208-210
 maternofetal transmission, 210
 prevention, 213-215
 varicella-zoster virus, 215-221
 fetal infection, 217-219
 maternal infection, 215-217
 maternofetal transmission, 217, 222-223
 neonatal infection, 219
 prevention, 219-221
 prevention, 213-215
 in TORCH complex, 731
 treatment, 910-913
 antiviral medications, 910-913
 background, 910
 Homeostasis of body fluids, 447-466
 body fluid tonicity, 448-449
 in congestive heart failure, 451-453
 angiotensin converting enzyme inhibitors, 461
 diuretics, 455-461
 extracellular fluid volume, 449-451
 fluid balance and distribution, 447-448
 and patent ductus arteriosus, 453-454
 See also *Fluid and electrolyte therapy, premature infant.*
 Hormones, and cardiac growth, 434-436
 actin role, 437-438
 Human immunodeficiency virus (HIV), 734-736
 background, 734
 congenital infections, 171-173
 laboratory diagnosis, 735-736
 in pregnancy, 189-202, 734-735
 antepartum care, 192-195
 antiviral agents, 195
 candidiasis, 195

- Human immunodeficiency virus (HIV)
(Continued)
in pregnancy, antepartum care, herpes,
simplex, 193-194
Kaposi's sarcoma, 195
Pneumocystis carinii pneumonia,
192-193
toxoplasmosis, 194-195
tuberculosis, 195
counseling and testing, 198-199
epidemiology, 189-190
intrapartum, 196-197
postpartum, 197-198
pregnancy effects on HIV disease, 190-
191
and neonatal outcome, 191
Human parvovirus B19. See *Parvovirus*
B19, human.
Hyaline membrane disease, in twin preg-
nancy, 128-130, 150-151
Hydranmios, pathophysiology of, 32
Hydrocephalus, congenital, 947-950
Hydronephrosis, congenital, 945-947
Hyperbilirubinemia, 982-985
Hyperoxemia, and retinopathy, 920-921
Hypertension, hereditary, and digoxin-like
immunoreactive substances, 517-518
neonatal, 567-585
blood pressure measurement, 567-569
causes of, 570-573
clinical signs and symptoms, 573-575
epidemiology, 569-570
evaluation in neonate and infant, 575-
577
management of, 577-579
prognosis, 579-580
pregnancy-induced, antenatal manage-
ment, 64-65, 82-83
Hypothermic arrest, 666
- IgM, total cord levels, in TORCH complex,
729-730
Immunoglobulin therapy, for neonatal sep-
sis, 761-767
Immunology, of chlamydial infections, 328-
331
Immunosuppression, and parvovirus B19 in-
fection, 278
Implantation, infection before, 164-166
viral, 164-165
infections after, 166-175
bacterial, 173-174
nonspecific and indirect effects, 166
protozoan, 174-175
viral, 167-173
Infant, very low birth weight, and mainte-
nance fluid therapy, 873-874
See also *Tiny infant outcome*.
- Infections, in pregnancy, antibiotic therapy
of newborn, 365-388
incidence of infection, 365-366
chlamydial infections, 321-350
diagnosis, 340-341
epidemiology, 326-328
immunologic factors, 328-331
microbiology, 322-325
neonatal infections, 335-340
postpartum endometritis, 334-335
psittacosis, 325
treatment, 341-344
congenital, 163-188
before conception, 163-164
before implantation, 164-166
after implantation, 166-175
perinatally acquired, 175-180
echovirus and group B coxsackievirus,
233-246
herpesvirus, 203-231
cytomegalovirus, 203-208
Epstein-Barr virus, 221-224
herpes simplex, 208-215
varicella-zoster virus, 215-221
human immunodeficiency virus (HIV),
189-202
antepartum, 192-195
counseling and testing, 198-199
epidemiology, 189-190
intrapartum, 196-197
postpartum, 197-198
pregnancy effects on HIV disease, 190-
191
influenza, 259-264
measles, 267-270
mumps, 264-267
parasites, 351-363
malaria, 358-362
toxoplasmosis, 354-358
parvovirus B19, 273-286
rubella, maternal and congenital syn-
drome, 247-257
syphilis, gestational and congenital, 287-
303
epidemiology, 287-289
followup and retreatment, 299-300
and pregnancy, 289-293
prevention, 293-297
treatment, complications, 297-298
neonatal, 298-299
tuberculosis, 305-319
clinical manifestations and diagnosis,
308-312
pathogenesis, 306-308
treatment, 312-317
See also *Streptococci, group B, antimicro-
bial prophylaxis*.
Influenza, 259-264
clinical course, 260-264
congenital malformations, 262-263

- maternal infection, 260-261
- nosocomial infection in neonate, 263-264
- transplacental passage and fetal infection, 261-262
- virus antigens, 259-260
- Inner-cell mass duplication, 16-19
- Inotropic and afterload-reducing agents, 467-489
 - cardiac physiology, 467-471
 - developmental aspects, 471-472
 - and digitalis glycosides, 494
 - vasoactive drug therapy, 473-479
 - dobutamine, 475-477
 - dopamine, 474-475
 - epinephrine, 478-479
 - isoproterenol, 477-478
 - vasodilators, 479-483
 - amrinone, 483
 - nitroglycerine, 481
 - nitroprusside, 481-483
- Intensive care, neonatal, and surfactant replacement therapy, 899-900
- Interventional cardiac procedures, 633-658
 - balloon atrial septostomy, 634-635
 - blade atrial septostomy, 635-637
 - coarctation of aorta, 644-648
 - native, 644-646
 - recurrent and postoperative obstructions, 647-648
 - device occlusion, 648-650
 - dilation of pulmonary valve in cyanotic congenital heart disease, 652-653
 - endomyocardial biopsy, 651
 - foreign body retrieval, 651
 - percutaneous pericardial drainage, 651-652
 - stenosis of individual pulmonary veins, 652
 - valvular aortic stenosis, 641-644
 - valvular pulmonary stenosis, 637-641
- Intrauterine treatment, digoxin uses, 505-506
- Iron, maternal, in twin pregnancy, 45
- Isoproterenol, 477-478
- Jarisch-Herxheimer reaction, 297-298
- Kaposi's sarcoma, HIV infection in pregnancy, 195
- Kernicterus, 965-990
 - bilirubin-binding assays, 975-982
 - pathophysiology, 968-974
 - phototherapy, 974-975
 - physiology of blood-brain barrier, 966-968
 - sequelae of hyperbilirubinemia, 982-985
- Kidney function, maternal, in twin pregnancy, 43-44
 - during transition to extrauterine life, 866-867
- Labor in twin pregnancy, 49-50, 87-91
 - analgesia, 111-113
 - anesthesia, 110-111
 - preterm, 71-77
 - antenatium management, 64
 - bedrest, prophylactic, 71-73
 - beta-sympathomimetic agents, 74
 - cervical cerclage, 73
 - delivery, and fetal lung maturation, 74-75
 - progesterone therapy, 73
 - treatment of, 74
- Light exposure, and retinopathy of prematurity, 924-925
- Listeria monocytogenes*, 180
- Lung maturity, in twin pregnancy, 48
 - amniocentesis for, 63
 - and premature labor, 74-75
- Lung surfactants, extract, 893-894
 - synthetic, 894-896
- Malaria, during pregnancy, 358-362
- Malformations in twin pregnancy, 3-4
- Measles, 267-270
 - clinical course, 268-270
 - fetal effects, 269-270
 - during pregnancy, 269
 - epidemiology, 267-268
 - virus, 270
- Membranes, premature rupture of (PROM), 851-862
 - management, 853-859
 - preterm, 856-859
 - very preterm, 855-856
 - mortality/morbidity, 853
 - prevention of, 853
- Morbidity and mortality, extremely low birth weight infants, 780-783
- of twin pregnancy, 3-6, 123-140
 - abnormal growth, 4
 - birth asphyxia, 128
 - congenital anomalies, 132-133
 - hyaline membrane disease, 128-130
 - incidence, 124-125
 - malformations, 3-4
 - maternal, 6-8
 - neurologic morbidity, 131-132
 - perinatal, 142
 - premature rupture of membranes, 853
 - prematurity, 4-5
 - prematurity/low birth weight rate/intrauterine growth

- Morbidity and mortality (*Continued*)
of twin pregnancy, respiratory morbidity,
130-131
retardation, 126-127
teenage pregnancies, fetal, 936
maternal, 936-939
neonatal, 935-936
trauma at delivery, 5-6
- Mother, in twin pregnancy, 41-47
alimentary system, 44
carbohydrate metabolism, 44
coagulation, 43
morbidity and mortality, 6-8
nutrition, 44-45
physical characteristics, 41-43
renal function, 43-44
respiratory function, 43
serum protein and electrolytes, 45-47
zinc, copper, and iron levels, 45
See also *Infections, in pregnancy; Twin pregnancy, antenatal complications.*
- Mouth, herpes infections, 908
- Mumps, 264-267
clinical course and epidemiology, 264-267
congenital malformations, 265
endocardial fibroelastosis, 265-266
postnatal infection, 266-267
virus, 264
- Myofibrils, in heart maturation, 427
- Myosin, in heart maturation, 428-434
developmental regulation, 433-434
heavy-chain distribution, 430-431
light-chain distribution, 431-433
- Neonatal problems in twins, 141-158
congenital malformation, 147-150
embryology, zygosity, placentation, 141-142
group B streptococcal disease, 151
growth and development, 151-153
hyaline membrane disease, 150-151
necrotizing enterocolitis, 151
parenting, 153-154
perinatal mortality, 142
prematurity, low birth weight, intrauterine development, 142-144
retinopathy of prematurity, 151
twin transfusion syndrome, 144-147
- Neurologic morbidity, in twin pregnancy, 131-132
- Newborn infants, antibiotic therapy, 365-388
administration route, 382
adverse effects, 386
bacterial infections, 367-368
blind therapy, 375-377
cephalosporins, third-generation, 380-381
diagnosis of infection, 368-372
dosage, 382
epidemiology, 366-367
evaluation, 380
incidence of infection, 365-366
monitoring of therapy, 384-385
new antibiotics, 381
pharmacology and pharmacokinetics, 372-375
policy, 375
problem areas, 377-380
toxicity, 385-386
treatment duration, 382-384
- chlamydial infections, 335-340
conjunctivitis, 335-337, 343-344
pneumonia, 337-340, 344
digoxin-like immunoreactive substances, 510-511
enterovirus infections, 236-240
clinical manifestations, 238-239
incidence, 236-237
mechanisms of transmission, 237-238
outbreaks in newborn nurseries, 240-241
severity and outcome, 239-240
herpes simplex infections, 210-213
influenza, nosocomial infection, 263-264
inotropic and afterload-reducing agents, 467-489
cardiac physiology, 467-471
developmental aspects, 471-472
guidelines for use, 484
inotropy, 473
vasoactive drug therapy, 473-479
vasodilators, 479-483
mumps infection, 266-267
sodium homeostasis, 516-517
syphilis infections, 298-300
tuberculosis, 306-308, 316-317
varicella infections, 219
See also *Cardiovascular disease in neonates.*
- Nitroglycerine, 481
Nitroprusside, 481-483
- Nutrition, maternal, in twin pregnancy, 44-45
- Oxygen toxicity, and retinopathy, 922-923
Oxygenation, extracorporeal membrane, 815-829
basic techniques, 817-818
complications and outcomes, 824-826
criteria for patient selection, 821-824
future considerations, 826-827
historical background, 818-821
therapeutic strategies, 816-817

- Pacing. See *Transesophageal pacing and electrocardiography*.
- Parasites, and pregnancy, 351-363
 malaria, 358-362
 toxoplasmosis, 354-358
- Parenting of twins, 153-154
- Parvovirus B19, human, 273-286
 clinical characteristics, 277-278
 aplastic crisis, 277-278
 arthritis, 278
 erythema infectiosum (Fifth disease), 277
 in immunosuppressed patients, 278
 and other diseases, 278
 diagnosis, 274-276
 epidemiology, 276-277
 and pregnancy, 278-282
 congenital anomalies, 279
 fetal death, 278-280
 in TORCH complex, 732-734
 virus characterization, 274
- Patent ductus arteriosus, body fluid homeostasis, 453-454
 digoxin effects, 504
 echocardiography, two-dimensional and Doppler, 524-528
- Penicillin, for syphilis, 293-294
 allergy and desensitization, 296-297
- Percutaneous pericardial drainage, 651-652
- Perinatal paradigm, 801-813
 neonatal care, 807-809
 obstetric care, 804-807
 residence for mothers, 813-812
- pH, physiologic, and normal oxygenation, 816-817
- Pharmacology and pharmacokinetics, antibiotic therapy of newborn, 372-375
 of digoxin, 498-503
- Phospholamban, 442
- Phototherapy, 974-975
- Placenta, 141-142
 in multiple pregnancy, 13-40
 classification, 14-15
 dizygotic, 14-15
 monozygotic, 15
 third type, 15
 diagnosis of zygosity, 20-25
 embryology of, 15-19
 dizygous, 19
 monozygous, 15-19
 etiology, 19-20
 pathology, 25-35
 dichorionic-diamnionic fused, 32-35
 dichorionic-diamnionic separate, 35
 monochorionic-diamnionic, 28-32
 monochorionic, monoamnionic, with conjoined twins, 27-28
- Pneumonia, chlamydial, 337-340, 344
 Pneumocystis carinii, in pregnancy, 192-193
- Polyhydramnios, antenatal management, 65
- Potassium balance, during transition to extrauterine life, 867
- Preeclampsia, and digoxin-like immunoreactive substances, 517-518
- Pregnancy, and B19 infection, 732-733
 and digoxin-like immunoreactive substances, 511, 517-518
 and Epstein-Barr virus infection, 737-740
 higher order multiple, 35-38
 and HIV infection, 734-735
 and parasites, 351-363
 malaria, 358-362
 toxoplasmosis, 354-358
 racial differences, 745-754
 risk factors, 750-752
 trends, 745-750
 twin. See *Twin pregnancy*.
 See also *Infections, in pregnancy; Teenage pregnancy*.
- Prematurity, in twin pregnancy, 4-5, 126-127, 142-144
- Prenatal care, controversies in, Baby Doe committees, 789-800
 assessment, 794-798
 ethical decisions, 794-795
 federal regulations and guidelines, 795-796
 legal problems, 796
 public image, 796-798
 assumptions and goals of ethics committees, 790-791
 origin, 789-790
 similarities and differences, 791-792
 suggestions, 798-799
 types of ethical questions, 792-794
- fluid and electrolyte therapy, 863-787
 homeostatic maintenance, and extrauterine life, 864-869
 metabolic basis for maintenance, 864
 and pathophysiology of diseases of prematurity, 869-874
- herpes simplex virus infections, 903-916
 diagnosis, 908-910
 epidemiology, 903-905
 neonatal infections, 905-908
 acquisition of infection, 905
 clinical presentation, 906
 intrapartum and postpartum infection, 906-908
 intrauterine infection, 906
 pathogenesis, 905-906
 treatment, 910-913
- kernicterus, 965-990
 bilirubin-binding assays, 975-982
 pathophysiology, 968-974
 phototherapy, 974-975
 physiology of blood-brain barrier, 966-968

Prenatal care (*Continued*)

- kernicterus, sequelae of hyperbilirubinaemia, 982-985
- oxygenation, extracorporeal membrane, 815-829
 - basic techniques, 817-818
 - complications and outcomes, 824-826
 - criteria for patient selection, 821-824
 - future considerations, 826-827
 - historical background, 818-821
 - therapeutic strategies, 816-817
- paradigm changes, 801-813
 - neonatal care, 807-809
 - obstetric care, 804-807
 - residence to mothers, 810-812
- premature rupture of membranes, 851-862
 - management, 853-859
 - mortality/morbidity, 853
 - prevention of, 853
- racial differences in pregnancy outcomes, 745-754
 - risk factors, 750-752
 - trends, 745-750
- retinopathy of prematurity, 917-928
 - description, 919
 - development of retina, 918-919
 - pathophysiology, 919-926
 - research priorities, 926
 - risk factors, 919
 - visual sequelae, 926
- rickets of prematurity, 879-790
 - causes of, 879-885
 - prevention, 885-886
- sepsis, neonatal, 755-771
 - exchange transfusion, 755-758
 - fibronectin, 767
 - granulocyte transfusions, 758-761
 - immunoglobulin therapy, 761-767
- streptococci, group B, antimicrobial prophylaxis, 831-850
 - ascertainment of cases, 844-845
 - blanket versus selective strategies, 833-837
 - cost-effectiveness, 845-846
 - regimen choice, 844
 - side effects, 845
 - timing of chemoprophylaxis, 837-844
- surfactant replacement therapy, 891-902
 - and neonatal intensive care, 899-900
 - outcome criteria, 896-898
 - side effects, 898-899
 - variety of surfactants, 892-896
- surgery, fetal, 943-953
 - congenital diaphragmatic hernia, 950-951
 - congenital hydrocephalus (ventriculomegaly), 947-950
 - congenital hydronephrosis, 945-947
 - future applications, 951
 - teenage pregnancy, 929-942
 - in future, 939
 - low birthweight outcomes, 933-935
 - maternal mortality, 936-939
 - neonatal mortality, 935-936
 - and other developed countries, 940
 - prenatal mortality, 936
 - trends in births, 929-933
 - tiny infant outcome, 773-788
 - antenatal and postnatal assessment of gestational age, 776-777
 - birth weight, gestational age, and intra-uterine growth failure, 777
 - definitions and terminology, 774-776
 - delivery type, effects on outcome, 778-780
 - extremely low birth weight infants, 780-785
 - obstetric correlates and determinants of outcome, 777-778
- TORCH complex, 727-744
 - diagnostic evaluation, 728-732
 - Epstein-Barr virus, 736-740
 - human immunodeficiency virus, 734-736
 - human parvovirus B19, 732-734
 - vitamin E therapy in high-risk neonates, 955-963
 - clinical problems, 957-959
 - normal absorption and deficiency states, 955-957
 - tocopherol prophylaxis for oxygen toxicity, 959-960
 - working guidelines, 960-961
- President's Commission, Baby Doe committees, 795-796
- Pressure overload, and cardiac actin, 437
- digoxin effects, 504
- Progesterone, prophylactic, and premature labor, 73
- Prophylaxis, antibiotic, and premature rupture of membranes, 857
 - antimicrobial. *See Streptococci, group B, antimicrobial prophylaxis.*
- Prostaglandin E₁, in open heart surgery, 661-662
- Proteins, and cytosolic calcium, 440-442
 - phospholamban, 442
 - sarcolemmal, 442
 - sarcoplasmic reticular Ca, Mg-dependent ATPase, 440-442
 - serum, maternal, in twin pregnancy, 45-47
- Protozoan infections, after implantation, 174-175
- Psitticosis, and pregnancy, 325
- Public image, Baby Doe committees, 796-798
- Pulmonary artery banding, 684-688

- Pulmonary atresia, with intact ventricular septum, 676-677
and tetralogy of Fallot, 675-676
Pulmonary disease, arterial markings, 546-549
chronic, digoxin effects, 504
venous marking, 549-552
Pulmonary valve, dilation of, in cyanotic congenital heart disease, 652-653
stenosis, 676
Pulmonary vein stenosis, 652
- Racial differences in pregnancy outcomes, 745-754
risk factors, 750-752
trends, 745-750
Receptors, digitalis, 492-493
Renal failure, and digoxin-like immunoreactive substances, 511
Renin-angiotensin system, and body fluid homeostasis, 450, 452
Reperfusion injury, 923
Residence for Mothers, 813-812
Respiratory distress syndrome, and maintenance fluid therapy, 870-871
Respiratory function in twin pregnancy, maternal, 43
morbidity, 130-131
Retinopathy of prematurity, 151, 917-928
description, 919
development of retina, 918-919
pathophysiology, 919-926
antioxidants, 923-924
gap-junction formation, 921-922
hyperoxemia, 920-921
immaturity role, 919-920
light exposure, 924-925
oxygen toxicity, 922-923
reperfusion injury, 923
systemic illness, 926
vasoconstriction, 921
research priorities, 926
risk factors, 919
visual sequelae, 926
vitamin E therapy, 959-960
Retroviral infections, before conception, 163-164
congenital, 171-173
Rickets of prematurity, 879-890
causes of, 879-885
prevention, 885-886
streptococcal sepsis, 833-834
Risk factors in pregnancy, racial differences, 750-752
RNA viruses, congenital infections, 168
Rubella, 247-257
congenital infections, 167-168
fetal infection, 250-253
maternal infections, 247-249
maternofetal transmission, 249
prevention, 253-255
in TORCH complex, 730-731
- Sarcolemma, in heart maturation, 426-427, 442
Sarcoplasmic reticulum, in heart maturation, 423-425
Ca, Mg-dependent ATPase, 440-442
Sepsis, neonatal, 755-771
exchange transfusion, 755-758
fibronectin, 767
granulocyte transfusion, 758-761
immunoglobulin therapy, 761-767
Septostomy, balloon atrial, 634-635
blade atrial, 635-637
Serologic tests, for chlamydial infections, 340
for syphilis, 289-290
Sexual partners, syphilis testing, 300
Shunts, systemic to pulmonary artery, 682-684
Skin, herpes infections, 908
Sodium homeostasis, and digoxin-like immunoreactive substances, 511-516
during transition to extrauterine life, 866
Spironolactone, 460-461
Steroids, in premature rupture of membranes, 856-857
Stillbirths, and enterovirus infections, 236
Streptococci, group B, antimicrobial prophylaxis, 831-850
ascertainment of cases, 844-845
blanket versus selective strategies, 833-837
maternal carriage, 834-837
risk factors, 833-834
congenital infections, 178-180
cost-effectiveness, 845-846
regimen choices, 844
side effects, 845
timing of chemoprophylaxis, 837-844
intrapartum, 841-844
postnatal, 838-841
prenatal, 838
in twins, 151
Sudden infant death syndrome. *See Arrhythmias, cardiac, and sudden infant death syndrome.*
Surfactant replacement therapy, 891-902
and neonatal intensive care, 899-900
outcome criteria, 896-898
side effects, 898-899
types, 892-896
extracts of lung surfactant, 893-894
from human amniotic fluid, 892-893
synthetic, 894-896

- Surgery, cardiac, digoxin uses, 504-505
 closed heart, for congenital heart disease, 681-697
 aortic valvular stenosis, 692-696
 atrial septectomy, 688-692
 palliative operations, 681-682
 pulmonary artery banding, 684-688
 systemic to pulmonary artery shunts, 682-684
 See also *Heart, open repair of defects; Interventional cardiac procedures.*
 fetal, 943-953
 congenital diaphragmatic hernia, 950-951
 congenital hydrocephalus (ventriculomegaly), 947-950
 congenital hydronephrosis, 945-946
 future applications, 951
 Syphilis, gestational and congenital, 173-174, 287-303
 epidemiology, 287-289
 followup and retreatment, 299-300
 infants, 300
 postpartum, 300
 during pregnancy, 299-300
 sexual partners, 300
 neonatal treatment, 298-299
 and pregnancy, 289-293
 clinical diagnosis, 290
 fetal infection, 290-291
 laboratory diagnosis, 292-293
 serologic tests, 289-290
 prevention, 293-297
 cephalosporins and chloramphenicol, 296
 erythromycin, 294-295
 penicillin, 293-294
 allergy and desensitization, 296-297
 prenatal care, 293
 tetracycline, 295-296
 treatment, 297-298
 failures, 298
 Jarisch-Herxheimer reaction, 297-298

 Tachycardias, supraventricular, digoxin uses, 505-506
 transesophageal stimulation for termination and initiation, 628
 See also *Arrhythmias.*
 Teenage pregnancy, 929-942
 comparison to other developed countries, 940
 future trends, 939
 low birthweight outcomes, 933-935
 mortality, fetal, 936
 maternal, 936-939
 neonatal, 935-936

 trends in births, 929-933
 mothers aged 10 to 14 years, 931-933
 mothers aged 15-19 years, 929-931
 Teratogenicity, and enterovirus infections, 236
 Tetracycline, for syphilis, 295-296
 Tetralogy of Fallot, with or without pulmonary atresia, 675-676
 Thiazides, 460
 Third factor, 511-516
 Thrombotic nonbacterial endocarditis, 588-590
 Tiny infant outcome, 773-788
 antenatal and postnatal assessment of gestational age, 776-777
 birth weight, gestational age, and intrauterine growth failure, effects on survival, 777
 definitions and terminology, 774-776
 delivery types, effects on outcome, 778-780
 extremely low birth weight, 780-785
 follow-up during infancy and childhood, 783-785
 neonatal and predischARGE morbidity and survival, 780-783
 obstetric correlates and determinants of outcome, 777-778
 Tocolysis, in premature rupture of membranes, 856
 prophylactic, in antepartum management, 61
 Tocopherol. See *Vitamin E therapy in high-risk neonates.*
 TORCH complex, 727-744
 diagnostic evaluation, 728-732
 cytomegalovirus, 730
 expanded TORCH, 732
 herpes simplex virus, 731
 rubella, 730-731
 total cord IgM, 729-730
 toxoplasmosis, 730
 Epstein-Barr virus, 736-740
 background, 736
 laboratory diagnosis, 736-737
 and pregnancy, 737-740
 human immunodeficiency virus, 734-736
 background, 734
 laboratory diagnosis, 735-736
 and pregnancy, 734-735
 human parvovirus B19, 732-734
 background, 732
 laboratory diagnosis, 733-734
 and pregnancy, 732-733
 Total anomalous pulmonary venous connection (TAPVC), 668-670
 interrupted aortic arch, 671-672
 nonobstructed, 670
 obstructed infracardiac, 668-669
 truncus arteriosus, 672-675

- Toxicity, and antibiotic therapy of newborn, 385-386
- Toxoplasma gondii*, 174-175
- Toxoplasmosis, and HIV infection, 194-195
during pregnancy, 354-358
in TORCH complex, 730
- Transesophageal pacing and electrocardiography, 619-631
diagnostic and therapeutic uses, 624-629
antiarrhythmic therapy evaluation, 629
atrial pacing, 627-628
complications, 629
esophageal ECG, 624-626
tachycardia, termination and initiation of, 628
ventricular pacing, 626-267
electrocardiography, 619-620
pacing, 620
techniques, 621-623
electrocardiogram recording, 621-622
electrode placement, 621
pacing, 622-623
- Transfusions, exchange, for neonatal sepsis, 755-758
- Transposition of great arteries, 667
- Triamterene, 460-461
- Tropomyosin, in heart maturation, 438-439
- Troponin, 440
- Truncus arteriosus, 672-675
- Tuberculosis, 305-319
clinical manifestations and diagnosis, 308-312
and HIV infection, 195
pathogenesis, 306-308
fetus and newborn, 306-308
maternal, 306
treatment, 312-317
congenital or neonatally acquired, 315-316
infant of tuberculous mother, 316-317
maternal, 312-314
prevention during pregnancy, 316
- Tumors, echocardiography of, 555-556
- Twin pregnancy, antepartum, complications, 79-96
anemia, 83
carbohydrate metabolism, diabetes mellitus, 83-84
congenital anomalies, 80
death of one fetus, 81-82
maternal hypertension, 82-83
twin discordance, 80-81
vanishing twin, 79
antepartum, management, 55-69
amniocentesis, 62-63
Doppler ultrasound, 63
fetal lung maturation, 63
genetic, 62-63
bed rest, 60-61
cervical cerclage, 61
death of one fetus, 65
diagnosis, early, 55-56
clinical, 56-57
diet, 60
maternal complications, 63-65
polyhydramnios, 65
pregnancy-induced hypertension, 64-65
preterm labor, 64
tocolysis, prophylactic, 61
ultrasonography, 57-59
diagnosis of twins, 57
fetal growth assessment, 58-59
zygosity determination, 57-58
visits and fetal surveillance, 61-62
delivery, anesthesia, 107-122
management of, 93-106
diagnosis, 8-10
fetal effects, 47-49
growth, 47-48
lung maturity, 48
umbilical cord measurement, 48-49
incidence, 1-3, 124-125
labor effects, 49-50
labor management, 87-91
labor, preterm, prevention and treatment of, 71-77
bedrest, prophylactic, 71-73
beta-sympathetic agents, 74
cervical cerclage, 73
delivery, and fetal lung maturation, 74-75
progesterone therapy, 73
maternal effects of, 41-53
alimentary system, 44
carbohydrate metabolism, 44
coagulation, 43
dietary zinc, copper, and iron, 45
nutrition, 44-45
physical characteristics, 41-43
proteins and electrolytes in serum, 45-47
renal function, 43-44
respiratory function, 43
morbidity and mortality factors, 3-6, 123-140
abnormal growth, 4
birth asphyxia, 128
congenital anomalies, 132-133
hyaline membrane disease, 128-130
incidence, 124-125
malformations, 3-4
neurologic morbidity, 131-132
prematurity/low birth weight rate/intrauterine growth retardation, 4-5, 126-127
respiratory morbidity, 130-131
trauma at delivery, 5-6
neonatal problems, 141-158
congenital malformations, 147-150

- Twin pregnancy (*Continued*)
 neonatal problems, embryology, zygosity, placenta, 141-142
 group B streptococcal disease, 151
 growth and development, 151-153
 hyaline membrane disease, 150-151
 necrotizing enterocolitis, 151
 parenting, 153-154
 perinatal mortality, 142
 prematurity, low birth weight, intra-uterine development, 142-144
 retinopathy of prematurity, 151
 twin transfusion syndrome, 144-147
 placenta, 13-40
 classification, 14-15
 embryology of, 15-19
 etiology, 19-20
 pathology, 25-35
 dichorionic-diamniotic fused, 32-35
 dichorionic-diamniotic separate, 35
 monochorionic, monoamniotic, with conjoined twins, 27-28
 monochorionic-diamniotic, 28-32
 zygosity, diagnosis of, 20-25
 Twin transfusion syndrome, monochorionic-diamniotic placenta, 30-32
 and neonatal problems, 144-147
- Ultrasonography, diagnosis of twins, 57
 energy effects on fetus, 561-562
 fetal growth assessment, 58-59
 zygosity determination, 57-58
- Umbilical cord, in twin pregnancy, 48-49
- Vaginal delivery, of twin pregnancy, 113-116
- Vanishing twin, 79
- Varicella-zoster virus, fetal infection, 217-219
 maternal infection, 215-217
 maternofetal transmission, 217
 neonatal infection, 219
 prevention, 219-221
- Vascular connections, in dichorionic placenta, 34-35
 in monochorionic-diamniotic placenta, 29-30
- Vasoconstriction, and retinopathy of prematurity, 921
- Vasodilators, 479-483
- Vegetations, echocardiography of, 553-555
- Ventricles, right-to-left shunt, 540-545
 septal defects, digoxin effects, 503
 echocardiography, two-dimensional and Doppler, 529-532
- Ventricular outflow obstruction, echocardiography of, 532-539
- Ventricular rhythm with intermediate rate (VRIR), 609-618
- Ventriculomegaly, 947-950
- Viral infections, after implantation, 167-173
 cytomegalovirus, 168-170
 other DNA viruses, 171
 other herpesviruses, 170-171
 other RNA viruses, 168
 retroviruses (HIV), 171-173
 rubella, 167-168
 perinatal, 176-168
 hepatitis B, 177-178
 herpes simplex, 176-177
 See also specific diseases.
- Vitamin E therapy in high-risk neonates, 955-963
 clinical problems, 957-959
 absorption and hydrolysis of esters, 957-958
 available products, 958-959
 storage, transport, and elimination, 958
 toxicity, 958
 normal absorption and deficiency states, 955-957
 supplementation, 956
 prophylaxis for oxygen toxicity, 959-960
 bronchopulmonary dysplasia, 959
 retinopathy of prematurity, 959-960
 periventricular/intraventricular hemorrhage, 960
 working guidelines, 960-961
- Volume overload, digoxin effects, 503-504
- Water, excretion of, 448
 during transition to extrauterine life, 864-866, 867
- Zinc, maternal, in twin pregnancy, 45
- Zygosity, and neonatal problems of twins, 141-142
 placental, 20-25
 ultrasonography, 57-58

